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ABSTRACT
Objectives To explore 6-month and 12-month
secukinumab effectiveness in patients with axial
spondyloarthritis (axSpA) overall, as well as across (1)
number of previous biologic/targeted synthetic disease-
modifying antirheumatic drugs (b/tsDMARDs), (2) time since
diagnosis and (3) different European registries.
Methods Real-life data from 13 European registries
participating in the European Spondyloarthritis Research
Collaboration Network were pooled. Kaplan-Meier with log-
rank test, Cox regression, χ² and logistic regression analyses
were performed to assess 6-month and 12-month
secukinumab retention, inactive disease/low-disease-activity
states (Bath Ankylosing Spondylitis Disease Activity Index
(BASDAI) <2/<4, Ankylosing Spondylitis Disease Activity
Score (ASDAS) <1.3/<2.1) and response rates (BASDAI50,
Assessment of Spondyloarthritis International Society (ASAS)
20/40, ASDAS clinically important improvement (ASDAS-CII)
and ASDAS major improvement (ASDAS-MI)).
Results We included 1860 patients initiating secukinumab
as part of routine care. Overall 6-month/12-month
secukinumab retention rates were 82%/72%, with
significant (p<0.001) differences between the registries
(6-month: 70–93%, 12-month: 53–86%) and across
number of previous b/tsDMARDs (b/tsDMARD-naïve: 90%/
84%, 1 prior b/tsDMARD: 83%/73%, ≥2 prior b/tsDMARDs:
78%/66%). Overall 6-month/12-month BASDAI<4 were
observed in 51%/51%, ASDAS<1.3 in 9%/11%, BASDAI50
in 53%/47%, ASAS40 in 28%/22%, ASDAS-CII in 49%/46%
and ASDAS-MI in 25%/26% of the patients. All rates differed
significantly across number of previous b/tsDMARDs, were
numerically higher for b/tsDMARD-naïve patients and varied
significantly across registries. Overall, time since diagnosis
was not associated with secukinumab effectiveness.
Conclusions In this study of 1860 patients from 13
European countries, we present the first comprehensive
real-life data on effectiveness of secukinumab in patients
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What is already known about this subject?
► Secukinumab has in RCTs shown efficacy in the
treatment of axSpA, but observational studies
confirming these findings are lacking.
What does this study add?
► Secukinumab retention, inactive disease, low-
disease-activity and response rates differed
significantly across number of previous b/
tsDMARDs, with overall better outcomes with less
previous use of b/tsDMARDs, whereas time since
diagnosis had no significant impact on outcomes.
► The overall 6- and 12-month secukinumab retention
was high and comparable to studies on TNFi.
► Response rates were lower than in RCTs, but post-
treatment disease states and response rates were
comparable to studies on TNFi.
How might this impact on clinical practice?
► The study supports the effectiveness of secukinumab
in the treatment of axSpA, but also underlines the
need for head-to-head studies on treatment
effectiveness of TNFi and IL-17 pathway inhibitors.
Spondyloarthritis
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with axSpA. Overall, secukinumab retention rates after 6 and 12 months of
treatment were high. Secukinumab effectiveness was consistently better
for bionaïve patients, independent of time since diagnosis and differed
across the European countries.
INTRODUCTION
Axial spondyloarthritis (axSpA) is a chronic, inflamma-
tory, rheumatic disease characterised by inflammation
and damage in the sacroiliac joints and spine, causing
inflammatory back pain, disability and impaired quality
of life.1 2 In patients with persistently high disease activity
despite conventional treatment, biologic disease-
modifying antirheumatic drugs (bDMARDs) are used,
most often tumour necrosis factor inhibitors (TNFi).3
In 2015, the new-mode-of-action drug secukinumab was
approved by the European Medicines Agency for use in
ankylosing spondylitis. This fully human IgG1 monoclo-
nal antibody targeting interleukin-17A4 has shown signif-
icant efficacy in the treatment of axSpA in randomised
controlled trials (RCTs).5–7 According to current Assess-
ment of Spondyloarthritis International Society (ASAS)-
EULAR recommendations, secukinumab is recom-
mended after failure of the first TNFi.3
There is to date limited real-world evidence on secuki-
numab treatment outcomes in patients with axSpA.8–10
Thus, the effectiveness of secukinumab, the impact of
previous bDMARD or targeted synthetic DMARD
(tsDMARD) use on secukinumab effectiveness in routine
care, as well as the impact of time since diagnosis have not
been studied in a large observational cohort of patients
with axSpA.
Hence, the primary aim of this study was to determine
the overall secukinumab retention rate in Europe after
12 months of treatment. Secondary aims were to deter-
mine 6-month retention rates and 6-month and 12-month
inactive disease, low-disease-activity (LDA) and response
rates. Primary and secondary aims were assessed overall as
well as compared across number of prior b/tsDMARDs,
across time since diagnosis and across European
registries.
METHODS
European Spondyloarthritis Research Collaboration Network
The European Spondyloarthritis Research Collaboration
Network (EuroSpA)11 was initiated in 2016/2017. Euro-
SpA aims to develop and investigate research questions by
secondary use of prospectively collected real-life data on
patients with SpA.11–13 So far, the collaboration includes
16 European registries, some of which have been collect-
ing data from as early as 1999. Research questions focus
on routine care treatment of patients with spondyloar-
thritis (SpA) in a European context, through pooling of
relevant variables from the individual registries. All data
are anonymised in the individual registries before upload
through a secure virtual private network pipeline to the
secured EuroSpA server, where the data are quality
checked and pooled before statistical analyses are
conducted.
Patients
For this study, anonymised data from patients with axSpA
treated with secukinumab in routine care from 13 coun-
tries in the EuroSpA were uploaded and pooled: ARTIS
(Sweden), RRBR (Romania), SCQM (Switzerland),
ATTRA (Czech Republic), DANBIO (Denmark), BIOBA-
DASER (Spain), TURKBIO (Turkey), NOR-DMARD
(Norway), biorx.si (Slovenia), Reuma.pt (Portugal),
GISEA (Italy), ROB-FIN (Finland) and ICEBIO (Iceland)
(ordered from highest to lowest number of included
patients). The data were collected independently of this
study, that is, by national quality registries that collect
information on any b/tsDMARDs. All patients were pro-
spectively followed in the different registries, although
the study was retrospectively designed with secondary
use of data already collected in the registries, that is,
planned after data collection had taken place, but before
data were available. To be included patients had to be
≥18 years old, have a diagnosis of axSpA as judged by the
treating rheumatologist, be previously secukinumab
naïve and have a registered start date of secukinumab.
Assessments
Assessments included demographics, time since diagnosis,
start and stop dates of secukinumab treatment, previous
b/tsDMARD treatment (including the TNFis adalimu-
mab, etanercept, infliximab, golimumab and certolizu-
mab, the costimulatory inhibitor abatacept, the anti-
B-cell agent rituximab, the interleukin (IL)-12/IL-23 inhi-
bitor ustekinumab, the IL-6 receptor inhibitor tocilizu-
mab, the IL-1 receptor inhibitor anakinra and the
tsDMARDs apremilast, baricitinib and tofacitinib), current
smoking status (yes/no), body mass index (kg/m2),
C reactive protein (CRP, mg/L), erythrocyte sedimenta-
tion rate (mm/h), visual analogue scales (0–100 mm) of
patient’s and evaluator’s global assessments, pain and fati-
gue (except for SCQM, biorx.si and RRBR which used
a 0–10 numeric rating scale) and Health Assessment Ques-
tionnaire (0–3). The following composite indices were
calculated based on their individual items: Bath Ankylos-
ing Spondylitis Disease Activity Index (BASDAI, 0–10),14
Bath Ankylosing Spondylitis Functional Index (BASFI,
0–10)15 and Ankylosing Spondylitis Disease Activity Score
(ASDAS; including BASDAI questions 2, 3 and 6, patient’s
global assessment and CRP).16 17 The following inactive
disease, LDA and response measures were calculated at
6-month and 12-month follow-up: BASDAI remission
defined as <2, BASDAI LDA defined as <4,18 ASDAS inac-
tive disease (<1.3),19 ASDAS LDA (<2.1),19 change in BAS-
DAI and ASDAS, BASDAI50 response (at least 50%
improvement in BASDAI score or an absolute change of
2 units on a 0–10 scale),18 ASAS20/40 response (including
RMD Open
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measures of physical function, pain, inflammation as
assessed by duration of morning stiffness and patient’s
global assessment),20 21 ASDAS clinically important
improvement (ASDAS-CII≥1.1) and ASDAS major
improvement (ASDAS-MI≥2.0).22
Primary and secondary outcomes
The primary outcome was the overall 12-month secukinu-
mab retention rate. Secondary outcomes were the overall
6-month secukinumab retention rate, and 6-month and
12-month inactive disease, LDA and response rates. Pri-
mary and secondary outcomes were compared across (1)
number of previous b/tsDMARDs (0/1/≥2), (2) time
since diagnosis (<2/2–4/>4 years) and (3) the different
European registries.
Statistical analyses
Statistical analyses were performed according to
a predefined statistical analysis plan. Normally distributed
data were presented as mean (SD) and skewed data as
median (IQR). Group comparisons of demographics and
baseline disease activity were performed with analysis of
variance (ANOVA), Kruskal-Wallis or χ² test, as appropriate.
All drug retention, disease state and response analyses
were performed at 6-month and 12-month follow-up.
Drug retention was explored by Kaplan-Meier analyses
with log-rank test. Cox regression analyses adjusted for
age, gender and time since diagnosis were applied for
comparisons of retention across number of previous b/
tsDMARDs (0/1/≥2) and across European registries, and
adjusted for age and gender for comparisons across time
since diagnosis (<2/2–4/>4 years).
Group comparisons of disease states, changes in BAS-
DAI/ASDAS and response rates were performed with
ANOVA, Kruskal-Wallis or χ² test, as well as with analysis
of covariance (ANCOVA) and logistic regression analyses
adjusted for age, gender and time since diagnosis (com-
parisons across number of previous b/tsDMARDs (0/1/
≥2) and across European registries), or age and gender
(comparisons across time since diagnosis (<2/2–4/
>4 years)), as appropriate. LUNDEX23 adjustments
(crude value adjusted for drug retention) were calculated
for disease states.
Multivariate Imputation by Chained Equations (includ-
ing 50 imputations) was performed for the Cox regres-
sion, ANCOVA and logistic regression analyses for 300
patients with missing data for time since diagnosis. The
remaining analyses were available case analyses. Number
of patients with available data for each of the analyses are
shown in table 1 and in online supplemental tables 1–5.
Observations were censored by the date of data extrac-
tion, date of death or end of registry follow-up, whichever
came first. The index date was defined as the secukinu-
mab treatment start date. Follow-up period was defined as
the period between index date and the end of the 12-
month study period, date of death or end of registry
follow-up/capture, whichever came first. A significance
level of 0.05 was set. No corrections for multiple
comparisons were performed. Statistical analyses were
performed with R version 3.4.4/3.6.1 and SPSS ver-
sion 25.
Ethics
The study was approved by the respective national data
protection agencies and research ethical committees
according to legal regulatory requirements in the partici-
pating countries. It was performed in accordance with the
Declaration of Helsinki and followed the Strengthening
the Reporting of Observational Studies in Epidemiology
guidelines.24
RESULTS
A total of 1860 patients with axSpAwere included, thereof
414 b/tsDMARD naïve patients, 448 patients previously
treated with 1 b/tsDMARD and 998 patients previously
treated with 2 or more b/tsDMARDs. The 1 prior b/
tsDMARD group included <10 patients who had pre-
viously been treated with ustekinumab and rituximab
and 444 patients previously treated with a TNFi.
tsDMARDs had previously been used by 14 patients, all
in the ≥2 prior b/tsDMARD group, including apremilast
by 10 patients and tofacitinib and baricitinib by <10
patients; they had all previously also been treated with
TNFi. The remaining 984 patients had previously exclu-
sively been treated with different bDMARDs, including
TNFi used by all of the patients, ustekinumab by 24
patients, abatacept by 27, rituximab by 12, tocilizumab
by 28 and anakinra by <10 patients (table 1).
Information on themodifiedNew York criteria were avail-
able in 664 patients and fulfilled in 514 of these patients,
and information on the ASAS criteria in 963 patients and
fulfilled in 799 of these patients. Furthermore, 97 patients
were registered as fulfilling the ASAS criteria but not the
modified New York criteria, that is, compatible with non-
radiographicaxSpA.
Patients were only included in the study if they had
been followed in the individual registries since start of
secukinumab treatment. Hence, date of secukinumab
initiation had no missing cases. Of the 1860 patients
included in the study, 916 patients were still using secuki-
numab at the date of data extraction, 659 patients had
a registered stop date of secukinumab, 240 patients had
a date of end of follow-up and the remaining 45 patients
were assumed to have ended secukinumab 12 months
after the last registered visit, in accordance with the pre-
defined statistical analysis plan.
Information on doses was not registered systematically.
Of 828 patients in whom doses were registered, 762
patients initiated secukinumab 150 mg/month and 66
patients 300 mg/month.
The patients started secukinumab treatment between
April 2015 and December 2018. Data cuts in the indivi-
dual registries were performed between October 2018
and September 2019. A total of 1270 of the 1860 patients
had started secukinumab treatment at least 52 weeks
Spondyloarthritis
Michelsen B, et al. RMD Open 2020;6:e001280. doi:10.1136/rmdopen-2020-001280 3
 on N
ovem










pen: first published as 10.1136/rm
























































































































































































































397 (27.5) NA 125 (27.9) 272 (27.3) 0.84
Certolizumab,
n (%)
76 (5.3) NA 27 (6.0) 49 (4.9) 0.45
Etanercept,
n (%)
362 (25.0) NA 115 (25.7) 247 (24.7) 0.76
Golimumab,
n (%)
170 (11.8) NA 75 (16.7) 95 (9.5) <0.001
Infliximab,
n (%)
357 (24.7) NA 82 (18.3) 275 (27.6) <0.001
Other, n (%) 8 (0.6) NA 4 (0.9) 4 (0.4) 0.21
Continued
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prior to the date of the data cut. b/tsDMARD-naïve
patients were younger, had shorter time since diagnosis,
higher baseline disease activity and a higher proportion
were men compared with patients treated with one prior,
or two or more prior, b/tsDMARDs.
Secukinumab drug retention overall and compared by previous
b/tsDMARD treatment
Overall, 6-month and 12-month secukinumab retention
rates were 82% and 72%, respectively, and differed sig-
nificantly (p≤0.001) across number of previous b/
tsDMARDs, with decreasing drug retention rates with
increasing previous b/tsDMARD use (6-/12-month: b/
tsDMARD naïve: 90%/84%, 1 prior b/tsDMARD: 83%/
73%, ≥2 prior b/tsDMARDs: 78%/66%; table 2, figure 1).
When adjusted for age, gender and time since diagno-
sis, patients who had used one previous b/tsDMARD or
two or more previous b/tsDMARDs were at higher risk of
discontinuing secukinumab before 12 months of treat-
ment compared with b/tsDMARD-naïve patients (HR
1.78, 95% CI 1.29 to 2.47 and HR 2.33, 95% CI 1.74 to
3.11, respectively; online supplemental figure 1).
Secukinumab retention according to reason for withdrawal
More patients withdrew from secukinumab due to loss of
efficacy (n=326) than adverse events (n=110) (figure 2).
Secukinumab retention rates according to time since
diagnosis
Drug retention of secukinumab was not associated with
time since diagnosis, when patients were stratified into
time <2 years, 2–4 years and >4 years since diagnosis
(online supplemental table 3). Additional adjustment
for age and gender gave similar findings (6 months,
p=0.83; 12 months, p=0.85).
Secukinumab retention rates across European countries
Significant heterogeneity in baseline demographics, dis-
ease activity measures and proportions of bionaïve
patients across different European countries were found
(online supplemental table 4). Secukinumab retention
rates after 6 and 12 months of treatment varied signifi-
cantly across the countries in EuroSpA (table 3, figure 3).
Adjustment for age, gender and time since diagnosis gave
similar findings (data not shown).
Inactive disease, LDA and response rates after 6 and
12 months of secukinumab treatment
Median BASDAI after 6 and 12 months of secukinumab
treatment were 3.9 and 3.9, and ASDAS 2.6 and 2.5,
respectively (table 2). Crude/LUNDEX-adjusted BAS-
DAI<2 was achieved by 26%/21% of the patients after
6 months and 25%/16% after 12 months, and BASDAI<4
by 51%/40% of the patients after 6 months and 51%/
32% after 12 months of treatment. Proportions of
patients achieving crude/LUNDEX-adjusted ASDAS
inactive disease after 6 and 12 months of treatment were
9%/7% and 11%/7%, and ASDAS low disease activity
24%/19% and 27%/17%, respectively. After 6 and
12 months of treatment, BASDAI50 response was
achieved by 53% and 47%, ASAS20 response by 40%
and 37%, ASAS40 response by 28% and 22%, ASDAS-
CII by 49% and 46% and ASDAS-MI by 25% and 26% of
the patients, respectively (table 2). Response rates in
patients having received ≥3 b/tsDMARDs can be found
in online supplemental table 5 and were overall compar-
able to the group of patients who had previously used ≥2
b/tsDMARDs. There were some differences in baseline
characteristics between patients with missing and non-
missing data for 6-month and 12-month response rates,
but these were not consistent across the different
response criteria (data not shown).
Disease states and response rates across number of previous
b/tsDMARDs
Crude and LUNDEX-adjusted inactive disease, LDA
and response rates after 6 and 12 months of treatment
varied statistically significantly across number of pre-
vious b/tsDMARDs (all p≤0.002), showing decreasing
effectiveness with increasing previous b/tsDMARD use.
Overall, the numerically highest rates were found in
bionaïve patients (table 2, figure 4). Adjustment for
age, gender and time since diagnosis gave similar results
(data not shown).
Inactive disease, LDA and response rates according to time
since diagnosis
Disease states and response rates at 6 and 12 months were
not significantly different between patients with time
since diagnosis <2 years, 2–4 years and >4 years, except















Missing, n (%) 76 (5.3) NA 20 (4.5) 56 (5.6) 0.40
n available n=1446 NA n=448 n=998
*Comparisons between b/tsDMARD-naïve, 1 prior and ≥2 prior b/tsDMARD-treated patients were performed with χ² test, ANOVA or Kruskal-
Wallis, as appropriate.
ASDAS, Ankylosing Spondylitis Disease Activity Score; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing
Spondylitis Functional Index; b/tsDMARD, biologic/targeted synthetic disease-modifying antirheumatic drug; csDMARD, conventional
synthetic disease-modifying antirheumatic drug.
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Median (95% CI) time in weeks to secukinumab
withdrawal due to loss of efficacy or adverse events
before 12 months†
21 (20–22) 22 (16–28) 21 (19–23) 21 (19–23) 0.21
BASDAI, median (IQR) 6 months 3.9 (1.8–5.9) 2.8 (1.4–4.1) 3.0
(1.5–5.7)
4.8 (2.7–6.6) <0.001
12 months 3.9 (1.9–6.3) 2.4 (1.3–3.9) 3.2
(1.7–6.0)
5.0 (2.6–6.8) <0.001
BASFI, median (IQR) 6 months 3.9 (1.8–6.3) 2.4 (0.7–4.7) 4.0
(1.3–6.3)
4.4 (2.4–6.6) <0.001
12 months 4.1 (1.8–6.5) 2.1 (0.5–4.3) 3.6
(1.4–6.4)
4.7 (2.7–6.7) <0.001
ASDAS, median (IQR) 6 months 2.6 (1.9–3.3) 2.2 (1.7–2.7) 2.4
(1.7–3.1)
2.8 (2.1–3.6) <0.001
12 months 2.5 (1.8–3.4) 1.9 (1.5–2.6) 2.3
(1.6–3.2)
2.8 (2.0–3.5) <0.001
BASDAI <2, % 6 months Crude 26% 37% 35% 18% <0.001
LUNDEXadjusted† 21% 34% 28% 13% <0.001
12 months Crude 25% 41% 29% 18% <0.001
LUNDEX-
adjusted†
16% 31% 18% 11% <0.001
BASDAI <4, % 6 months Crude 51% 71% 60% 40% <0.001
LUNDEX-
adjusted†
40% 65% 47% 30% <0.001
12 months Crude 51% 76% 56% 39% <0.001
LUNDEX-
adjusted†
32% 57% 36% 23% <0.001
ASDAS <1.3, % 6 months Crude 9% 13% 13% 6% 0.001
LUNDEX-
adjusted†
7% 12% 11% 5% <0.001
12 months Crude 11% 18% 15% 7% 0.002
LUNDEX-
adjusted†
7% 13% 9% 4% 0.002
ASDAS <2.1, % 6 months Crude 24% 32% 26% 20% 0.002
LUNDEX-
adjusted†
19% 29% 21% 15% <0.001
12 months Crude 27% 44% 27% 21% <0.001
LUNDEX-
adjusted†
17% 33% 17% 12% <0.001
Change in BASDAI from
baseline to 6 months
Mean (SD) −2.1 (2.6) −3.7 (2.5) −2.1 (2.5) −1.4 (2.3) <0.001






−1.0 (−2.8, 0.1) <0.001
Change in BASDAI from
baseline to 12 months
Mean (SD) −2.1 (2.5) −3.3 (2.6) −2.1 (2.3) −1.4 (2.4) <0.001
Continued
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2 or more prior
b/tsDMARDs
(n=998) P value*






−1.1 (−2.5, 0.0) <0.001
Change in ASDAS from
baseline to 6 months
Mean (SD) −1.1 (1.3) −2.0 (1.1) −1.1 (1.3) −0.7 (1.2) <0.001






−0.6 (−1.6, 0.0) <0.001
Change in ASDAS from
baseline to 12 months
Mean (SD) −1.1 (1.3) −2.0 (1.3) −1.2 (1.2) −0.7 (1.2) <0.001









6 months Crude 53% 79% 53% 40% <0.001
LUNDEX-
adjusted†
42% 72% 42% 30% <0.001
12 months Crude 47% 67% 53% 36% <0.001
LUNDEX-
adjusted†
29% 51% 34% 21% <0.001
ASAS20
response, %
6 months Crude 40% 66% 41% 32% <0.001
LUNDEX-
adjusted†
32% 60% 32% 24% <0.001
12 months Crude 37% 69% 35% 29% <0.001
LUNDEX-
adjusted†
23% 52% 22% 17% <0.001
ASAS40
response, %
6 months Crude 28% 57% 23% 19% <0.001
LUNDEX-
adjusted†
22% 52% 18% 14% <0.001
12 months Crude 22% 55% 19% 14% <0.001
LUNDEX-
adjusted†
14% 42% 12% 8% <0.001
ASDAS-CII, % 6 months Crude 49% 77% 52% 35% <0.001
LUNDEX-
adjusted†
39% 70% 41% 26% <0.001
12 months Crude 46% 72% 52% 33% <0.001
LUNDEX-
adjusted†
29% 55% 33% 19% <0.001
ASDAS-MI, % 6 months Crude 25% 46% 25% 15% <0.001
LUNDEX-
adjusted†
20% 42% 20% 11% <0.001
12 months Crude 26% 51% 27% 17% <0.001
LUNDEX-
adjusted†
16% 39% 17% 10% <0.001
*Drug retention rates were compared by Kaplan-Meier with log-rank test, continuous measures by ANOVA or Kruskal-Wallis, as appropriate,
and proportions by χ² test.
†Patients with at least 12 months from secukinumab start to date of data cut.
ASAS20/40, Assessment of Spondyloarthritis International Society 20/40 response; ASDAS, Ankylosing Spondylitis Disease Activity Score;
ASDAS-CII, ASDAS clinically important improvement (≥1.1); ASDAS-MI, ASDAS major improvement (≥2.0); ASAS20/40, Assessment of
Spondyloarthritis International Society 20/40 response; b/tsDMARD, biologic/targeted synthetic disease-modifying antirheumatic drug; BAS-
DAI, Bath Ankylosing Spondylitis Disease Activity Index; BASDAI50, at least 50% improvement in BASDAI score or an absolute change of 2 (on
a 0–10 scale); BASFI, Bath Ankylosing Spondylitis Functional Index.
Number of available cases for each of the analyses are shown in online supplemental table 1.
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supplemental table 3). Adjustment for age and gender
gave similar results.
Disease states and response rates across the European
registries
Disease states and response rates after 6 and 12months of
treatment varied significantly across the registries in
EuroSpA, except for ASDAS inactive disease (table 3).
Adjustment for age, gender and time since diagnosis did
not change this (data not shown).
DISCUSSION
In this study of 1860 patients from 13 European coun-
tries, we present the first comprehensive real-life data on
effectiveness of secukinumab in patients with axSpA.
Overall, secukinumab retention rates after 6 and
12 months of treatment were high (82% and 72%,
respectively). Importantly, effectiveness differed signifi-
cantly across number of previous b/tsDMARDs, with bio-
naïve patients consistently having numerically better
secukinumab retention as well as disease state and
response rates. Time since diagnosis did not impact on
secukinumab drug retention, inactive disease/LDA or
response rates, with few exceptions for 6-month BASDAI
outcomes. Significant differences between the European
registries were found.
To date, only a few small observational studies on secuki-
numab effectiveness in axSpA have been published, includ-
ing a UK study of 76 patients that reported a trend towards
improved 6-month BASDAI and BASFI responses,10 an
Italian study of 39 patients with axSpA that reported good
2-year effectiveness of secukinumab9 and a German pilot
study of 13 patients that reported 2-year clinical improve-
ment and regression of spinal inflammation as assessed by
MRI.8 Therefore, this real-life, international multicentre
study from large observational cohorts represents an
important addition to the RCTs on secukinumab. Interest-
ingly, data on secukinumab retention from RCTs are
scarce. In the MEASURE 1 trial, the 2-year secukinumab
retention was 78%,25 and in the MEASURE 2 trial, the
3-year retention rate was 86% for secukinumab 150 mg
every 4 weeks.6 In the MEASURE 3 trial, the 1-year reten-
tion rate was 87% in the group of patients whowere initially
randomised to 150mg secukinumab,7 which is higher than
the overall 1-year retention rate of 72% in this real-life
study. Compared to the patients in the MEASURE 2 and 3
trials, the patients in our study were older (mean age 47 vs
42 and 43 years), had lower baseline BASDAI (mean BAS-
DAI 6.0 vs 6.6 and 7.0), longer time since diagnosis (9.9 vs
7.0 and 6.0 years), a lower proportion were TNFi-naïve
(22% vs 61% and 57%) and we included both patients
with radiographic axSpA and patients with non-
radiographic axSpA, whereas only patients with radio-
graphic axSpA were included in the MEASURE 2 and 3
trials.6 7 Due to these differences in patient characteristics
and, perhaps most importantly in study design, no valid
conclusion on the comparison of secukinumab effective-
ness across these studies may be drawn.
The 12-month secukinumab retention rate for the b/
tsDMARD-naïve patients in this study (84%) was similar to
the recently reported 12-month retention rate to first-line
TNFi in patients with axSpA in Europe (80%)11 as well as
to other studies on first-line TNFi treatment.26 Retention
to a first TNFi in axSpA is in general known to be higher
than to a second or third TNFi.27 Of note, we report
similar findings for secukinumab in this study, with numeri-
cally higher secukinumab retention for b/tsDMARD-naïve
patients compared with patients treated with one and two
or more previous b/tsDMARDs. Thus, this study supports
Figure 1 Pooled 12-month secukinumab retention rates
for patients with axial spondyloarthritis in the European
Spondyloarthritis Research Collaboration Network stratified
by previous biologic/targeted synthetic disease-modifying
antirheumatic drug (b/tsDMARD) treatment (log-rank test;
p<0.001).
Figure 2 Secukinumab retention rates due to adverse events
(AE) and loss of efficacy (LOE, Kaplan-Meier plot; for 29
patients, it was not distinguished by the registries whether
reason for withdrawal was due to AE or LOE).
RMD Open
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the effectiveness of using secukinumab as first-line
bDMARD in the routine management of axSpA.
For b/tsDMARD-naïve patients, achievement of 12-
month BASDAI<4 (76%) and ASAS20/40 response
(69%/55%) in the current study were comparable to first-
time TNFi-treated patients with axSpA in a recently pub-
lished large-scale European study, in which 12-month
BASDAI<4 was achieved by 75% and ASAS20/40 by
67%/53% of the patients, respectively.11 In the same
study, ASDAS inactive disease was achieved by a higher
proportion of patients than in the current study (35% vs
18%). It should be emphasised, however, that several
parameters, including time since diagnosis and baseline
disease activity (ASDAS and BASDAI), were markedly
higher in the secukinumab-treated patients than in the
TNFi-treated patients, limiting direct comparisons.
Compared with the MEASURE 2 trial, 12-month
response rates for secukinumab were lower in our study
including BASDAI50 (47% vs 51%), mean change in BAS-
DAI (−2.1 vs −3.2), ASAS20 (37% vs 74%) and ASAS40
response (22% vs 57%).6 These differences were less pro-
nounced for b/tsDMARD-naïve patients (forASAS20, 69%
in the present study vs 80% in theMEASURE2 trial and for
ASAS40, 55% vs 63%).6 In theMEASURE 3 trial, ASAS20/
40 response rates at week 52 were 54%/41%, respectively,
for the 150 mg secukinumab group.7
Figure 4 Bar charts of proportions of patients achieving different disease state and response rates after 6 and 12 months of
secukinumab treatment compared across previous biologic/targeted synthetic disease-modifying anti-rheumatic drug (b/
tsDMARD) treatment. ASAS20/40, Assessment of Spondyloarthritis International Society 20/40 response; ASDAS CII, ASDAS
clinically important improvement (≥1.1); ASDAS MI, ASDAS major improvement (≥2.0); BASDAI, Bath Ankylosing Spondylitis
Disease Activity Index; BASDAI50, 50% improvement in BASDAI.
Figure 3 Twelve-month secukinumab retention rates com-
pared across patients with axial spondyloarthritis in different
European registries (Kaplan-Meier with log-rank test; ICEBIO
(Iceland) and 12-month number at risk for TURKBIO (Turkey)
are excluded from the plot due to <10 patients).
RMD Open
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Of note, comparison of treatment outcomes across dif-
ferent studies is challenging due to heterogeneity in study
populations and inclusion criteria and valid conclusions
may usually not be drawn. Direct comparison of the effi-
cacy of IL-17 pathway inhibition and TNFi in a head-to-
head design as first-line b/tsDMARD treatment in axSpA is
warranted28 29 as well as more observational studies on the
long-term effectiveness of IL-17 pathway inhibition.
Fewer patients withdrew from secukinumab due to
adverse events than lack of efficacy. Whereas about 6%
of the patients in our study withdrew from secukinumab
up to week 52 due to adverse events, 4% of the patients in
the initial 150mg secukinumab group in theMEASURE 3
trial withdrew from secukinumab due to adverse events
up to week 52.7
The major strengths of this study are the inclusion
of large cohorts of patients from observational regis-
tries across Europe, reflecting routine care in a wide
range of European countries, and the reporting of 12-
month observational data on secukinumab. The lim-
itations of the study are the inherent limitations of
registry studies compared to RCTs, that is, a lower
data quality than in RCTs, for example, missing data
on response outcomes across the registries. The use of
the BASDAI cut-offs <2 and <4 was chosen. There is
no consensus as yet on the best cut-off for BASDAI
remission in axSpA. However, these cut-offs were pre-
specified, a cut-off of 4 has previously been used for
active disease,18 and we also assessed ASDAS inactive
disease and ASDAS LDA in line with the current
recommendations.2 Furthermore, we assessed several
other response criteria specifically developed for
axSpA.18 Heterogeneity in secukinumab effectiveness
across the registries was seen. Importantly, the propor-
tions of bionaïve patients varied considerably across
registries and may explain some of the heterogeneity
in effectiveness across the registries. Furthermore,
number of included patients varied considerably
across the registries, which may also challenge direct
comparisons. Still, one of the major advantages of
data pooling is the overall high number of patients,
enabling to explore research questions often not fea-
sible in a single register.
In conclusion, in this large-scale real-life study, the
overall 12-month secukinumab retention was high,
with differences between the European registries.
Response and rates of favourable disease states were
lower than for RCTs on secukinumab, but comparable
to available real-world data on TNFi. Drug retention,
favourable disease states and response rates differed
significantly across the number of previous b/
tsDMARDs, showing overall better outcomes with less
previous use of b/tsDMARDs, whereas time since diag-
nosis had no impact on secukinumab effectiveness. The
study supports the effectiveness of secukinumab in the
treatment of axSpA, but also underlines the need for
head-to-head studies on treatment effectiveness of TNFi
and IL-17 pathway inhibitors.
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